Table I. Diabetes incidences after LCMV... | Rockefeller University Press

Table I.

Diabetes incidences after LCMV infection and various antibody treatments

Treatment	Control	Vα14	Control + α-GalCer	Control	Cd1d^−/−
	10⁵ PFU	10⁵ PFU	10⁵ PFU	10⁴ PFU	10⁴ PFU
None	10/12	0/12	1/12	6/12	12/12
Anti-CD25	12/12	11/12^a	10/12^a	12/12^a	ND
Control isotype	10/12	0/12	1/12	6/12	ND
Anti–TGF-β	11/12	10/12^a	10/12^a	10/12^a	ND
Control isotype	10/12	0/12	0/12	7/12	ND
120G8	11/12	10/12^a	10/12^a	10/12^a	ND
Control isotype	10/12	0/12	1/12	6/12	ND
Anti-CD62L	10/12	11/12^a	10/12^a	ND	ND
Control isotype	10/12	1/12	0/12	ND	ND

Treatment	Control	Vα14	Control + α-GalCer	Control	Cd1d^−/−
	10⁵ PFU	10⁵ PFU	10⁵ PFU	10⁴ PFU	10⁴ PFU
None	10/12	0/12	1/12	6/12	12/12
Anti-CD25	12/12	11/12^a	10/12^a	12/12^a	ND
Control isotype	10/12	0/12	1/12	6/12	ND
Anti–TGF-β	11/12	10/12^a	10/12^a	10/12^a	ND
Control isotype	10/12	0/12	0/12	7/12	ND
120G8	11/12	10/12^a	10/12^a	10/12^a	ND
Control isotype	10/12	0/12	1/12	6/12	ND
Anti-CD62L	10/12	11/12^a	10/12^a	ND	ND
Control isotype	10/12	1/12	0/12	ND	ND

Incidence of T1D 20 d after LCMV infection with 10⁴ or 10⁵ PFU of Ins-NP mice treated with anti-CD25, anti–TGF-β, 120G8, or anti-CD62L mAbs or with respective control isotype, as indicated. n = 12 for each group of mice.

P-values <0.05 for mAb-treated mice compared with untreated mice.

[ViewLarge]